FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100943089> ?p ?o ?g. }

• W2100943089 endingPage "700" @default.
• W2100943089 startingPage "688" @default.
• W2100943089 abstract "Abstract Purpose: MUC4 shows aberrant expression in early pancreatic lesions and a high specificity for pancreatic cancer. It thus has a high potential to be a sensitive and specific biomarker. Unfortunately, its low serum level limits its diagnostic/prognostic potential. We here report that a multifaceted acute phase protein lipocalin 2, regulated by MUC4, could be a potential diagnostic/prognostic marker for pancreatic cancer. Experimental Designs and Results: Overexpression/knockdown, luciferase reporter and molecular inhibition studies revealed that MUC4 regulates lipocalin 2 by stabilizing HER2 and stimulating AKT, which results in the activation of NF-κB. Immunohistochemical analyses of lipocalin 2 and MUC4 showed a significant positive correlation between MUC4 and lipocalin 2 in primary, metastatic tissues (Spearman correlation coefficient 0.71, P = 0.002) from rapid autopsy tissue sample from patients with pancreatic cancer as well as in serum and tissue samples from spontaneous KRASG12D mouse pancreatic cancer model (Spearman correlation coefficient 0.98, P &lt; 0.05). Lipocalin 2 levels increased progressively with disease advancement (344.2 ± 22.8 ng/mL for 10 weeks to 3067.2 ± 572.6 for 50 weeks; P &lt; 0.0001). In human pancreatic cancer cases, significantly elevated levels of lipocalin 2 were observed in patients with pancreatic cancer (148 ± 13.18 ng/mL) in comparison with controls (73.27 ± 4.9 ng/mL, P = 0.014). Analyses of pre- and postchemotherapy patients showed higher lipocalin 2 levels in prechemotherapy patients [121.7 ng/mL; 95% confidence interval (CI), 98.1–150.9] in comparison with the postchemotherapy (92.6 ng/mL; 95% CI, 76.7–111.6; P = 0.06) group. Conclusions: This study delineates the association and the downstream mechanisms of MUC4-regulated elevation of lipocalin-2 (via HER2/AKT/NF-κB) and its clinical significance for prognosis of pancreatic cancer. Clin Cancer Res; 20(3); 688–700. ©2013 AACR." @default.
• W2100943089 created "2016-06-24" @default.
• W2100943089 creator A5002662464 @default.
• W2100943089 creator A5005591732 @default.
• W2100943089 creator A5006831359 @default.
• W2100943089 creator A5013058673 @default.
• W2100943089 creator A5026061991 @default.
• W2100943089 creator A5038278493 @default.
• W2100943089 creator A5041701143 @default.
• W2100943089 creator A5053044176 @default.
• W2100943089 creator A5061921070 @default.
• W2100943089 creator A5066667381 @default.
• W2100943089 creator A5077344460 @default.
• W2100943089 creator A5080815834 @default.
• W2100943089 creator A5085256777 @default.
• W2100943089 creator A5090025086 @default.
• W2100943089 date "2014-02-01" @default.
• W2100943089 modified "2023-10-11" @default.
• W2100943089 title "MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer" @default.
• W2100943089 cites W1523218371 @default.
• W2100943089 cites W1554868555 @default.
• W2100943089 cites W1590994864 @default.
• W2100943089 cites W1963967547 @default.
• W2100943089 cites W1965521903 @default.
• W2100943089 cites W1967930627 @default.
• W2100943089 cites W1978674708 @default.
• W2100943089 cites W1986692800 @default.
• W2100943089 cites W1995409011 @default.
• W2100943089 cites W1999629941 @default.
• W2100943089 cites W2000707384 @default.
• W2100943089 cites W2001868613 @default.
• W2100943089 cites W2004682964 @default.
• W2100943089 cites W2006674808 @default.
• W2100943089 cites W2010142785 @default.
• W2100943089 cites W2027480690 @default.
• W2100943089 cites W2033955020 @default.
• W2100943089 cites W2045356233 @default.
• W2100943089 cites W2049092824 @default.
• W2100943089 cites W2050484748 @default.
• W2100943089 cites W2054598829 @default.
• W2100943089 cites W2066135299 @default.
• W2100943089 cites W2070524341 @default.
• W2100943089 cites W2073361927 @default.
• W2100943089 cites W2073863460 @default.
• W2100943089 cites W2076211055 @default.
• W2100943089 cites W2103953318 @default.
• W2100943089 cites W2106464827 @default.
• W2100943089 cites W2108520616 @default.
• W2100943089 cites W2109120261 @default.
• W2100943089 cites W2111893587 @default.
• W2100943089 cites W2122361911 @default.
• W2100943089 cites W2128154344 @default.
• W2100943089 cites W2138063658 @default.
• W2100943089 cites W2141341148 @default.
• W2100943089 cites W2145515954 @default.
• W2100943089 cites W2146797845 @default.
• W2100943089 cites W2149121581 @default.
• W2100943089 cites W2150312232 @default.
• W2100943089 cites W2153359367 @default.
• W2100943089 cites W2159818270 @default.
• W2100943089 cites W2161497232 @default.
• W2100943089 cites W2161817637 @default.
• W2100943089 cites W2163157778 @default.
• W2100943089 cites W2335472123 @default.
• W2100943089 doi "https://doi.org/10.1158/1078-0432.ccr-13-2174" @default.
• W2100943089 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3946494" @default.
• W2100943089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24240113" @default.
• W2100943089 hasPublicationYear "2014" @default.
• W2100943089 type Work @default.
• W2100943089 sameAs 2100943089 @default.
• W2100943089 citedByCount "35" @default.
• W2100943089 countsByYear W21009430892014 @default.
• W2100943089 countsByYear W21009430892015 @default.
• W2100943089 countsByYear W21009430892016 @default.
• W2100943089 countsByYear W21009430892017 @default.
• W2100943089 countsByYear W21009430892018 @default.
• W2100943089 countsByYear W21009430892019 @default.
• W2100943089 countsByYear W21009430892020 @default.
• W2100943089 countsByYear W21009430892021 @default.
• W2100943089 countsByYear W21009430892022 @default.
• W2100943089 countsByYear W21009430892023 @default.
• W2100943089 crossrefType "journal-article" @default.
• W2100943089 hasAuthorship W2100943089A5002662464 @default.
• W2100943089 hasAuthorship W2100943089A5005591732 @default.
• W2100943089 hasAuthorship W2100943089A5006831359 @default.
• W2100943089 hasAuthorship W2100943089A5013058673 @default.
• W2100943089 hasAuthorship W2100943089A5026061991 @default.
• W2100943089 hasAuthorship W2100943089A5038278493 @default.
• W2100943089 hasAuthorship W2100943089A5041701143 @default.
• W2100943089 hasAuthorship W2100943089A5053044176 @default.
• W2100943089 hasAuthorship W2100943089A5061921070 @default.
• W2100943089 hasAuthorship W2100943089A5066667381 @default.
• W2100943089 hasAuthorship W2100943089A5077344460 @default.
• W2100943089 hasAuthorship W2100943089A5080815834 @default.
• W2100943089 hasAuthorship W2100943089A5085256777 @default.
• W2100943089 hasAuthorship W2100943089A5090025086 @default.
• W2100943089 hasBestOaLocation W21009430891 @default.
• W2100943089 hasConcept C121608353 @default.

• next